These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 8695345)

  • 61. Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
    Wu HG; Choy H
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):13-8. PubMed ID: 12375796
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Topoisomerase I inhibitors: topotecan and irinotecan.
    Jones SF; Burris HA
    Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772
    [No Abstract]   [Full Text] [Related]  

  • 63. [Irinotecan (CPT-11) therapy for advanced gastric cancer].
    Sakata Y
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():386-92. PubMed ID: 11424411
    [No Abstract]   [Full Text] [Related]  

  • 64. Irinotecan in the treatment of colorectal cancer: clinical overview.
    Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
    J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
    Clarke SJ; Yip S; Brown C; van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ;
    Eur J Cancer; 2011 Aug; 47(12):1826-36. PubMed ID: 21665462
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.
    Choy H; MacRae R
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):31-6. PubMed ID: 11221019
    [TBL] [Abstract][Full Text] [Related]  

  • 67. DNA topoisomerase I-targeting drugs as radiation sensitizers.
    Chen AY; Choy H; Rothenberg ML
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Topoisomerase I inhibitors in the treatment of head and neck cancer.
    Murphy BA; Cmelak A; Burkey B; Netterville J; Shyr Y; Douglas S; Smith W
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):47-52. PubMed ID: 11497232
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modulation of camptothecin analogs in the treatment of cancer: a review.
    Kehrer DF; Soepenberg O; Loos WJ; Verweij J; Sparreboom A
    Anticancer Drugs; 2001 Feb; 12(2):89-105. PubMed ID: 11261892
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
    McDonald AC; Brown R
    Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
    Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Camptothecin schedule and timing of administration with irradiation.
    Rich TA; Kirichenko AV
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):37-41. PubMed ID: 11301839
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
    Nagourney RA; Sommers BL; Harper SM; Radecki S; Evans SS
    Br J Cancer; 2003 Nov; 89(9):1789-95. PubMed ID: 14583785
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
    Kümler I; Brünner N; Stenvang J; Balslev E; Nielsen DL
    Breast Cancer Res Treat; 2013 Apr; 138(2):347-58. PubMed ID: 23512247
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CPT-11: an original spectrum of clinical activity.
    Rothenberg ML
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Benefit-risk assessment of irinotecan in advanced colorectal cancer.
    Glimelius B
    Drug Saf; 2005; 28(5):417-33. PubMed ID: 15853443
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise.
    Khaiwa N; Maarouf NR; Darwish MH; Alhamad DWM; Sebastian A; Hamad M; Omar HA; Orive G; Al-Tel TH
    Eur J Med Chem; 2021 Nov; 223():113639. PubMed ID: 34175539
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Jun; 4(3):152-67. PubMed ID: 11768329
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.